Chemo - radiation best for bladder cancer, study finds

By Maureen Salamon, HealthDay Reporter
Chemo + radiation best for bladder cancer, study finds
Adding fluorouracil, mitomycin C led to significantly better survival rates.

(HealthDay) -- The addition of two well-tolerated chemotherapy drugs to radiation therapy led to significantly longer survival rates among patients with muscle-invasive bladder cancer.

In a new study splitting 360 patients into groups receiving radiation alone or radiation plus chemotherapy, British researchers found that those undergoing combined therapies had a 67 percent rate of local disease-free survival after two years, compared with 54 percent in the radiation group. Five-year overall survival rates were 48 percent in the chemo-radiation group, compared with 35 percent in the radiation-only group.

"Overall, the results establish that the addition of chemotherapy to radiotherapy should become standard practice for organ-preserving treatments of ," said Dr. Manish Vira, director of the fellowship program in urologic oncology at the Arthur Smith Institute for Urology in Lake Success, N.Y. "The tried-and-true treatment method is still [bladder removal] and certainly we are moving toward a more multi-disciplinary approach."

The study is published April 19 in the .

About 385,000 cases of bladder cancer are diagnosed annually worldwide, according to study authors, with the average age at diagnosis over 70. For those whose cancer has invaded the , five-year survival rates are about 45 percent regardless of treatment.

For younger, healthier patients, bladder removal -- known as radical cystectomy -- is considered the gold standard of care for . But older patients with co-existing medical conditions may not be as well-equipped to tolerate complications of the procedure, experts said.

The new study, the largest late-stage trial of its kind, was conducted at 45 medical facilities in the United Kingdom. Patients were randomly assigned to undergo daily radiation alone or radiation along with two , fluorouracil and mitomycin C. In addition to improved , the number of patients needing bladder removal as a "salvage therapy" -- because other treatments failed -- was lower among those receiving plus chemotherapy.

Adverse effects from the chemotherapy -- including diarrhea, sore mouth or suppression of blood cell production -- were low among participants and were managed by lowering drug dosages, said study author Dr. Nicholas James, a professor of clinical oncology at the University of Birmingham. in England.

Cost of the chemotherapy drugs is relatively inexpensive, he said -- about $1,600, plus pharmacy and intravenous administration costs.

"We were pleasantly surprised by the overall results, particularly the low reported toxicity in the chemo-radiotherapy arm compared to the radiotherapy-only group," James said. "We feel the results are sufficient to change practice . . . the drugs are cheap and safety was good in an elderly population."

More information: The U.S. National Library of Medicine has more about bladder cancer.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Recommended for you

New breast cancer imaging method promising

18 minutes ago

The new PAMmography method for imaging breast cancer developed by the University of Twente's MIRA research institute and the Medisch Spectrum Twente hospital appears to be a promising new method that could ...

Palliation is rarely a topic in studies on advanced cancer

43 minutes ago

End-of-life aspects, the corresponding terminology, and the relevance of palliation in advanced cancer are often not considered in publications on randomized controlled trials (RCTs). This is the result of an analysis by ...

Breast cancer replicates brain development process

48 minutes ago

New research led by a scientist at the University of York reveals that a process that forms a key element in the development of the nervous system may also play a pivotal role in the spread of breast cancer.

Is genetic instability the key to beating cancer?

2 hours ago

Cancerous tumors may be poised at the edge of their own destruction, an insight that could help researchers find new, more effective treatments, suggest SFI External Professor Ricard Solé and colleagues in an April 9 paper ...

Phase 3 study may be game-changer for acute myeloid leukemia

6 hours ago

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine ...

User comments